Ottobock appoints Dr. Katarzyna Mazur-Hofsaess to the Management Board
- Photo Info
- Download
Ottobock appoints Dr. Katarzyna Mazur-Hofsaess to the Management Board
Change on the Management Board following the scheduled end of Stefan Heidenreich’s term of office
Duderstadt, 24 June 2026
Ottobock SE & Co. KGaA, the listed global MedTech company, has appointed Dr. Katarzyna Mazur-Hofsaess to its Management Board effective 22 June 2026. She succeeds Stefan Heidenreich, whose regular five-year term on the Management Board has come to an end.
“With Dr. Katarzyna Mazur-Hofsaess, we are gaining a proven expert in international medical technology and healthcare. Her experience in global companies and her medical background will be a valuable addition to our Board,” says Professor Hans Georg Näder, Chairman of the Management Board of Ottobock SE & Co. KGaA.
Dr. Mazur-Hofsaess has many years of international experience in medical technology and healthcare. From 2018 to 2025, she was a member of the Management Board of Fresenius Medical Care and CEO of the company MedTech segment Care Enablement. Prior to that, she was responsible for the EMEA region at Zimmer Biomet, the US-based specialist in joint replacement solutions. Earlier in her career, she held positions at Abbott Diagnostics and Roche Polska. She is also currently active as an independent, non-executive Director at Smith & Nephew.
A physician by training, Dr. Mazur-Hofsaess studied and earned her doctorate at the Medical University of Gdańsk. She also completed management studies at the Warsaw School of Economics and the University of Minnesota. She began her professional career at the University Clinical Centre in Gdańsk.
Stefan Heidenreich is stepping down from the Management Board following the scheduled end of his regular five-year term of office. As Deputy Chairman of the Management Board, he played a key role in shaping the company’s strategic development. Ottobock expressly thanks him for his work and the expertise he contributed to the company’s development into a listed company.
About Ottobock Ottobock, a listed global MedTech champion, combines over 100 years of tradition with outstanding innovative strength in the fields of prosthetics, neuro-orthotics and exoskeletons. Ottobock develops innovative fitting solutions for people with limited mobility and is driving the digitalization of the industry. Founded in Berlin in 1919, the company has business activities in 45 countries with nearly 9,300 employees (FTEs) worldwide and operates the largest international patient care network with around 420 patient care clinics. Ottobock is shaping the future of human bionics with a strong R&D ratio in the products and components business and over 2,600 patents and patent applications. Ottobock’s mission of improving freedom of movement, quality of life and independence is deeply rooted in the company's DNA, as is its social commitment: Ottobock has been a partner and supporter of the Paralympics since 1988.
Media contact: Ottobock SE & Co. KGaA Merle Florstedt Head of Corporate Communications Mobile +49 151 441 616 25 Merle.florstedt@ottobock.de
Investor Relations contact: Ottobock SE & Co. KGaA Julia Hartmann VP Investor Relations Mobile +49 151 556 848 07 Julia.Hartmann@ottobock.de
Ottobock SE & Co. KGaA, Firmensitz: Duderstadt, Deutschland, Handelsregister & -nummer: Amtsgericht Göttingen, HRB 205339; phG: Ottobock Management SE, Firmensitz: Duderstadt, Deutschland, Handelsregister & -nummer: Amtsgericht Göttingen, HRB 205183; Vorsitzender des Verwaltungsrats: Professor Hans Georg Näder; Geschäftsführende Direktoren: Oliver Jakobi (CEO/CSO), Dr. Arne Kreitz (CFO), Martin Böhm (CXO), Arne Jörn (COO/CTO); Vorsitzender des Aufsichtsrats der Ottobock SE & Co. KGaA: Dr. Bernd Bohr